Physician profile
Calvin Han
NPI 1376743872
$5,120.96
in general payments reported to CMS, 2019-2025
59 companies · $975 in 2025
The $975 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $490 · 2020: $116 · 2021: $400 · 2022: $455 · 2023: $1,160 · 2024: $1,526 · 2025: $975.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,275 · Education: $386.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,275.14 |
| Education | $385.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $508.17 | 2019-2025 | Rybrevant, Tecvayli, Darzalex |
| E.R. Squibb & Sons, L.L.C. | $423.77 | 2019-2025 | Opdivo |
| Novartis Pharmaceuticals Corporation | $349.27 | 2022-2025 | |
| Pharmacosmos Therapeutics INC. | $283.30 | 2023-2024 | Monoferric, Cosela |
| Incyte Corporation | $249.12 | 2020-2024 | Jakafi, Pemazyre, Monjuvi |
| Lilly USA, LLC | $223.99 | 2019-2023 | Verzenio, Jaypirca, Retevmo |
| Daiichi Sankyo INC. | $190.73 | 2021-2025 | Enhertu, Datroway, Vanflyta |
| Syndax Pharmaceuticals, INC. | $148.20 | 2025 | Revuforj |
| Sobi, INC | $145.42 | 2023-2024 | |
| Gilead Sciences, INC. | $137.35 | 2021-2025 | Trodelvy |
| Merck Sharp & Dohme LLC | $134.55 | 2019-2025 | Keytruda, Reblozyl, Welireg |
| Celgene Corporation | $122.23 | 2019-2024 | Opdualag, Pomalyst, Reblozyl |
| Genzyme Corporation | $120.33 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $111.97 | 2019-2025 | |
| Abbvie INC. | $104.00 | 2025 |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Calvin Han listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.